Poseida Therapeutics, Inc.

$8.91 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Join the waitlist

About Poseida Therapeutics, Inc.

Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company has discovered and are developing a broad portfolio of product candidates in a variety of indications based on its core platforms, including its non-viral piggyBac deoxyribonucleic acid (DNA) Modification System, Cas-CLOVER site-specific gene editing system and nanoparticle- and adeno-associated virus (AAV)-based gene delivery technologies. The Company’s product candidate portfolio includes P-BCMA-101, P-PSMA-101, P-BCMA-ALLO1, P-MUC1C-ALL01, Dual CAR, P-OTC-101 and P-MMUT-101.

Stock Analysis

last close $8.95
1-mo return 1.6%
3-mo return -3.6%
avg daily vol. 403.33T
52-week high 17.62
52-week low 7.63
market cap. $589M
forward pe -
annual div. -
roe -230.8%
ltg forecast 2.7%
dividend yield -
annual rev. $--
inst own. 43.7%
baraka

Join the waitlist for early access and a chance to earn $50 in free stock

Join the waitlist